ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma.
Yttrium-90
liver function
radioembolization
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Jul 2021
28 Jul 2021
Historique:
received:
15
07
2021
revised:
21
07
2021
accepted:
23
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
Selective internal radiation therapy (SIRT) is an innovative treatment of hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI) score was designed to better evaluate liver functions in HCC. We studied, retrospectively, data from patients treated with SIRT for HCC. The primary endpoint was the occurrence of radioembolization-induced liver disease (REILD). The secondary endpoint was overall survival (OS). 222 patients were studied. The ALBI grade 1 patients had significantly less REILD (3.4%) after the first SIRT than ALBI grade 2 or 3 patients (16.8%, The baseline ALBI grade is a strong predictor of REILD. The baseline ALBI score and variations of ALBI are prognostic after SIRT.
Sections du résumé
BACKGROUND
BACKGROUND
Selective internal radiation therapy (SIRT) is an innovative treatment of hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI) score was designed to better evaluate liver functions in HCC.
METHODS
METHODS
We studied, retrospectively, data from patients treated with SIRT for HCC. The primary endpoint was the occurrence of radioembolization-induced liver disease (REILD). The secondary endpoint was overall survival (OS).
RESULTS
RESULTS
222 patients were studied. The ALBI grade 1 patients had significantly less REILD (3.4%) after the first SIRT than ALBI grade 2 or 3 patients (16.8%,
CONCLUSIONS
CONCLUSIONS
The baseline ALBI grade is a strong predictor of REILD. The baseline ALBI score and variations of ALBI are prognostic after SIRT.
Identifiants
pubmed: 34359695
pii: cancers13153794
doi: 10.3390/cancers13153794
pmc: PMC8345032
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
J Hepatol. 2012 Feb;56(2):464-73
pubmed: 21816126
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
J Vasc Interv Radiol. 2006 Aug;17(8):1251-78
pubmed: 16923973
Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):635-43
pubmed: 26455499
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Liver Int. 2017 Jan;37(1):101-110
pubmed: 27514012
Am J Clin Oncol. 2018 Sep;41(9):861-866
pubmed: 28418940
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Br J Cancer. 2016 Mar 29;114(7):744-50
pubmed: 27022825
J Gastrointest Oncol. 2020 Aug;11(4):715-723
pubmed: 32953155
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1695-1704
pubmed: 31098749
Lancet Oncol. 2017 Dec;18(12):1624-1636
pubmed: 29107679
Cancers (Basel). 2019 Jun 24;11(6):
pubmed: 31238514
World J Gastroenterol. 2014 Jan 21;20(3):786-94
pubmed: 24574751
Cancer Treat Rev. 2018 Jul;68:16-24
pubmed: 29783126
Hepatology. 2013 Mar;57(3):1078-87
pubmed: 23225191
Major Probl Clin Surg. 1964;1:1-85
pubmed: 4950264
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Liver Int. 2016 Dec;36(12):1821-1828
pubmed: 27214151
Trials. 2014 Dec 03;15:474
pubmed: 25472660
J Vasc Interv Radiol. 2016 Jun;27(6):795-802
pubmed: 27038686
Lancet Oncol. 2018 Feb;19(2):e70
pubmed: 29413471
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29
pubmed: 33166497
Cancer. 2008 Apr 1;112(7):1538-46
pubmed: 18260156